<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336645</url>
  </required_header>
  <id_info>
    <org_study_id>SHP615-301</org_study_id>
    <nct_id>NCT03336645</nct_id>
  </id_info>
  <brief_title>Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and pharmacokinetics of&#xD;
      MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a&#xD;
      healthcare setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Response Rate</measure>
    <time_frame>From start of study drug administration up to 30 minutes post-dose</time_frame>
    <description>Response rate was defined as the percentage of participants with therapeutic success. Therapeutic success was defined as the cessation of visible seizure activity within 10 minutes with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615 without the need for additional rescue medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours</measure>
    <time_frame>From start of study drug administration up to 1, 4 and 6 hours post-dose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Time to Resolution of Seizures (Convulsions)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>Time to resolution of seizures (convulsions) was calculated as time from IP administration to the end of the initial seizure or administration of rescue anti-convulsant medication, whichever occurs first. Initial seizure referred to the seizure that triggered the use of the IP. Number of participants with time to resolution of seizures (convulsions) from the administration of SHP615 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Time to Recovery of Consciousness</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>Time to recovery of consciousness (in minutes) was calculated only for participants who lost consciousness pre-dose at time from investigational product administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Number of participants with time to recovery of consciousness were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE)</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE, 10 minutes after a single dose of SHP615 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Failed to Respond to the Treatment With SHP615</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>Treatment failure/non-responder was defined as participants with continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, for 10 mins or more after a single dose of the IP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of SHP615 in Plasma at 10 Minutes (C10)</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>Concentration of SHP615 in plasma at 10 minutes were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SHP615</measure>
    <time_frame>1, 3, 6 hours post-dose</time_frame>
    <description>Cmax of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma</measure>
    <time_frame>Pre-dose, 10 minutes post-dose</time_frame>
    <description>AUC0-10 of SHP615 in plasma were reported. Here &quot;min ng/mL&quot; was minutes nanogram per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma</measure>
    <time_frame>Pre-dose, 60 minutes post-dose</time_frame>
    <description>AUC0-60 of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma</measure>
    <time_frame>Pre-dose, 180 minutes post-dose</time_frame>
    <description>AUC0-180 of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma</measure>
    <time_frame>Pre-dose, 1, 3, and 6 hours post-dose</time_frame>
    <description>AUC(0-infinity) of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at Maximum Concentration (Tmax) of SHP615 in Plasma</measure>
    <time_frame>1, 3, and 6 hours post-dose</time_frame>
    <description>Tmax of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (T1/2) of SHP615 in Plasma</measure>
    <time_frame>1, 3, and 6 hours post-dose</time_frame>
    <description>T1/2 of SHP615 in plasma were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Respiratory Depression</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt; 92 percent (%) measured at 10, 30 minutes, and 4, 6, and 24 hours post-dose (i.e, &lt; 92 % on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]) ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose</measure>
    <time_frame>Baseline, 24 hours post-dose</time_frame>
    <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Change from baseline in riker sedation-agition scale at 24 hours post-dose were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Oxygen Saturation Percentage at 24 Hours Post-dose</measure>
    <time_frame>Baseline, 24 hours post-dose</time_frame>
    <description>Oxygen saturation at baseline was measured and recorded on room air. The investigator had recorded the oxygen saturation, oxygen delivery system and amount of oxygen administered during the study. Change from baseline in oxygen saturation percentage at 24 hours post-dose were reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>SHP615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP615</intervention_name>
    <description>SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).</description>
    <arm_group_label>SHP615</arm_group_label>
    <other_name>Midazolam hydrochloride oromucosal solution</other_name>
    <other_name>MHOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants whose corrected gestational age is greater than or equal&#xD;
             to (&gt;=) 52 weeks (gestational weeks plus the number of weeks after birth) and less&#xD;
             than (&lt;) 18 years (and weight greater than [&gt;] 5 kilogram [kg]), at the time of&#xD;
             investigational product administration. If the participant's exact age is not known,&#xD;
             the participant should be excluded.&#xD;
&#xD;
          -  Parent, guardian, or legally authorized representative (LAR) of the child provides&#xD;
             informed consent (and assent, when applicable per Shire policy and country&#xD;
             regulations) to participate in the study prior to participation in any protocol&#xD;
             specific procedures. The participant may be prescreened by the investigator in their&#xD;
             clinical practice and the parent, guardian, or LAR may sign informed consent before&#xD;
             the participant presents to the healthcare setting for treatment of the seizure.&#xD;
&#xD;
          -  Participant with generalized tonic-clonic SE with seizures accompanied by loss of&#xD;
             consciousness with any of the following characteristics persistent at the time of&#xD;
             study drug administration:&#xD;
&#xD;
               1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions&#xD;
                  within the preceding hour&#xD;
&#xD;
               2. Currently presenting with seizure (convulsive) and 2 or more convulsions in&#xD;
                  succession without recovery of consciousness&#xD;
&#xD;
               3. Currently presenting with a single seizure (convulsive) lasting &gt;=5 mins&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who are pregnant, suspected to be pregnant, or nursing.&#xD;
&#xD;
          -  Subjects with major trauma, not necessarily restricted to the head, as the cause of&#xD;
             the seizure.&#xD;
&#xD;
          -  Subjects with seizures due to illegal drug or acute alcoholic intoxication.&#xD;
&#xD;
          -  Subjects with known or suspected recurrent seizures due to illegal drug or alcohol&#xD;
             withdrawal.&#xD;
&#xD;
          -  Subjects with history of seizures of psychogenic origin.&#xD;
&#xD;
          -  Subjects with seizures due to severe encephalitis or meningitis, as determined by the&#xD;
             PI&#xD;
&#xD;
          -  Subjects with known history of hypersensitivities, non-responsiveness or&#xD;
             contraindications to benzodiazepines (ie, clinically significant respiratory&#xD;
             depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea,&#xD;
             glaucoma with closed angle, use of concomitant drugs determined by the investigator to&#xD;
             have a contraindication to the use of benzodiazepines.)&#xD;
&#xD;
          -  Subjects with a known history of benzodiazepine abuse.&#xD;
&#xD;
          -  Subjects who, in the judgment of the healthcare provider, have not responded to&#xD;
             previous administrations of midazolam systemic therapies, including Midafresa and/or&#xD;
             Dormicum.&#xD;
&#xD;
          -  Subjects who need emergent surgical intervention and general anesthesia/intubation.&#xD;
&#xD;
          -  Subjects with significant hypotension and cardiac dysrhythmia (example [eg],&#xD;
             atrioventricular [AV] block of second or third degree, VT [ventricular tachycardia]).&#xD;
&#xD;
          -  Subjects who have been receiving human immunodeficiency virus (HIV) protease&#xD;
             inhibitors or HIV reverse transcriptase inhibitors.&#xD;
&#xD;
          -  Subjects with current hypoglycemia (glucose &lt;60 milligram per deciliter [mg/dL]) upon&#xD;
             presentation at the hospital or healthcare setting.&#xD;
&#xD;
          -  Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the&#xD;
             healthcare provider.&#xD;
&#xD;
          -  Subjects have used an investigational product or been enrolled in a clinical study&#xD;
             (including vaccine studies) that, in the investigator's opinion, may impact this&#xD;
             Shire-sponsored study.&#xD;
&#xD;
          -  Subjects has received antiseizure medication prior to arrival in the healthcare&#xD;
             setting.&#xD;
&#xD;
          -  Subjects has prior placement of a vagus nerve stimulator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>216 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Fujimi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <state>Gifu Prefecture</state>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Kawadacho</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Minami-Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <state>Okayama Prefecture</state>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Owada Shinden</state>
        <zip>276-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Children's Medical Center Tochigi</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama-ken</state>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Institute of Epilepsy and Neurological Disorders</name>
      <address>
        <city>Shizuoka</city>
        <state>Shizuoka Prefecture</state>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital(NW)</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Hokkaido Medical Center</name>
      <address>
        <city>Hokkaidō</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nishi Niigata Chuo National Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center(NW)</name>
      <address>
        <city>Obu</city>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0914</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakano Children's Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>535-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital(NW)</name>
      <address>
        <city>Osaka</city>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center(NW)</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center Hospital, NCNP</name>
      <address>
        <city>Tokyo</city>
        <zip>187-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Yamadaoka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center(NW)</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <results_first_submitted>July 6, 2020</results_first_submitted>
  <results_first_submitted_qc>July 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seizure</keyword>
  <keyword>Midazolam hydrochloride</keyword>
  <keyword>Convulsive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03336645/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03336645/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03336645/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03336645/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 3</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03336645/Prot_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 28 study centers in the Japan between 23 October 2017 (first participant first visit) and 19 August 2019 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 25 participants were enrolled, received treatment and completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set consisted of all participants who had received a single dose of the investigational product (IP), regardless of whether IP administration was documented to be complete or not on the IP administration page of the electronic case report form (eCRF).</population>
      <group_list>
        <group group_id="B1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.63" spread="4.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Response Rate</title>
        <description>Response rate was defined as the percentage of participants with therapeutic success. Therapeutic success was defined as the cessation of visible seizure activity within 10 minutes with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615 without the need for additional rescue medication.</description>
        <time_frame>From start of study drug administration up to 30 minutes post-dose</time_frame>
        <population>Full Analysis Set (FAS) consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response Rate</title>
          <description>Response rate was defined as the percentage of participants with therapeutic success. Therapeutic success was defined as the cessation of visible seizure activity within 10 minutes with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615 without the need for additional rescue medication.</description>
          <population>Full Analysis Set (FAS) consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours</title>
        <description>Percentage of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
        <time_frame>From start of study drug administration up to 1, 4 and 6 hours post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours</title>
          <description>Percentage of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sustained Absence for at least 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained Absence for at least 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained Absence for at least 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Time to Resolution of Seizures (Convulsions)</title>
        <description>Time to resolution of seizures (convulsions) was calculated as time from IP administration to the end of the initial seizure or administration of rescue anti-convulsant medication, whichever occurs first. Initial seizure referred to the seizure that triggered the use of the IP. Number of participants with time to resolution of seizures (convulsions) from the administration of SHP615 were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Time to Resolution of Seizures (Convulsions)</title>
          <description>Time to resolution of seizures (convulsions) was calculated as time from IP administration to the end of the initial seizure or administration of rescue anti-convulsant medication, whichever occurs first. Initial seizure referred to the seizure that triggered the use of the IP. Number of participants with time to resolution of seizures (convulsions) from the administration of SHP615 were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Time to Recovery of Consciousness</title>
        <description>Time to recovery of consciousness (in minutes) was calculated only for participants who lost consciousness pre-dose at time from investigational product administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Number of participants with time to recovery of consciousness were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Time to Recovery of Consciousness</title>
          <description>Time to recovery of consciousness (in minutes) was calculated only for participants who lost consciousness pre-dose at time from investigational product administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Number of participants with time to recovery of consciousness were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE)</title>
        <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE, 10 minutes after a single dose of SHP615 were reported.</description>
        <time_frame>10 minutes post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE)</title>
          <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE, 10 minutes after a single dose of SHP615 were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Failed to Respond to the Treatment With SHP615</title>
        <description>Treatment failure/non-responder was defined as participants with continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, for 10 mins or more after a single dose of the IP.</description>
        <time_frame>10 minutes post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Failed to Respond to the Treatment With SHP615</title>
          <description>Treatment failure/non-responder was defined as participants with continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, for 10 mins or more after a single dose of the IP.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (date and time of the IP administration and seizure cessation for the initial seizure; participants with no recurrence of seizure within 30 minutes post-dose) performed after the administration of the IP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of SHP615 in Plasma at 10 Minutes (C10)</title>
        <description>Concentration of SHP615 in plasma at 10 minutes were reported.</description>
        <time_frame>10 minutes post-dose</time_frame>
        <population>Pharmacokinetic (PK) set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of SHP615 in Plasma at 10 Minutes (C10)</title>
          <description>Concentration of SHP615 in plasma at 10 minutes were reported.</description>
          <population>Pharmacokinetic (PK) set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of SHP615</title>
        <description>Cmax of SHP615 in plasma were reported.</description>
        <time_frame>1, 3, 6 hours post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of SHP615</title>
          <description>Cmax of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma</title>
        <description>AUC0-10 of SHP615 in plasma were reported. Here &quot;min ng/mL&quot; was minutes nanogram per milliliter.</description>
        <time_frame>Pre-dose, 10 minutes post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma</title>
          <description>AUC0-10 of SHP615 in plasma were reported. Here &quot;min ng/mL&quot; was minutes nanogram per milliliter.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>min ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma</title>
        <description>AUC0-60 of SHP615 in plasma were reported.</description>
        <time_frame>Pre-dose, 60 minutes post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma</title>
          <description>AUC0-60 of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>min ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2965" spread="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma</title>
        <description>AUC0-180 of SHP615 in plasma were reported.</description>
        <time_frame>Pre-dose, 180 minutes post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma</title>
          <description>AUC0-180 of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>min ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4411" spread="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma</title>
        <description>AUC(0-infinity) of SHP615 in plasma were reported.</description>
        <time_frame>Pre-dose, 1, 3, and 6 hours post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma</title>
          <description>AUC(0-infinity) of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>min ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5847" spread="2599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time at Maximum Concentration (Tmax) of SHP615 in Plasma</title>
        <description>Tmax of SHP615 in plasma were reported.</description>
        <time_frame>1, 3, and 6 hours post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time at Maximum Concentration (Tmax) of SHP615 in Plasma</title>
          <description>Tmax of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="15.5" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life (T1/2) of SHP615 in Plasma</title>
        <description>T1/2 of SHP615 in plasma were reported.</description>
        <time_frame>1, 3, and 6 hours post-dose</time_frame>
        <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (T1/2) of SHP615 in Plasma</title>
          <description>T1/2 of SHP615 in plasma were reported.</description>
          <population>PK set consisted of all participants who received a single dose of the IP and for whom at least 1 PK blood sample was collected post-dose. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="90.6" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Respiratory Depression</title>
        <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt; 92 percent (%) measured at 10, 30 minutes, and 4, 6, and 24 hours post-dose (i.e, &lt; 92 % on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]) ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Respiratory Depression</title>
          <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt; 92 percent (%) measured at 10, 30 minutes, and 4, 6, and 24 hours post-dose (i.e, &lt; 92 % on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]) ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Persistent Decrease in Oxygen Saturation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in Respiratory Effort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose</title>
        <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Change from baseline in riker sedation-agition scale at 24 hours post-dose were reported.</description>
        <time_frame>Baseline, 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose</title>
          <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Change from baseline in riker sedation-agition scale at 24 hours post-dose were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>Score on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with TEAEs were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with TEAEs were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Oxygen Saturation Percentage at 24 Hours Post-dose</title>
        <description>Oxygen saturation at baseline was measured and recorded on room air. The investigator had recorded the oxygen saturation, oxygen delivery system and amount of oxygen administered during the study. Change from baseline in oxygen saturation percentage at 24 hours post-dose were reported.</description>
        <time_frame>Baseline, 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Oxygen Saturation Percentage at 24 Hours Post-dose</title>
          <description>Oxygen saturation at baseline was measured and recorded on room air. The investigator had recorded the oxygen saturation, oxygen delivery system and amount of oxygen administered during the study. Change from baseline in oxygen saturation percentage at 24 hours post-dose were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of the IP, regardless of whether IP administration was documented to be complete or not on the IP administration page of the eCRF. Here, the number of participants analyzed refer to the participants evaluable for this outcome.</population>
          <units>Percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration to follow-up (8 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (3 months to less than [&lt;] 1 year received 2.4 milligram [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS) / SHP615 on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure cluster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
      <email>ClinicalTransparency@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

